Preclinical studies have shown that CXCR4 antagonists, such as AMD3100, in combination with PD-1 inhibitors, can effectively overcome the immunosuppressive tumor microenvironment and enhance antitumor immune responses. This evidence concerns the gene CXCR4 and neoplasm.